RT Journal Article
T1 Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis.
A1 Arriola, Edurne
A1 Gonzalez-Cao, Maria
A1 Domine, Manuel
A1 De-Castro, Javier
A1 Cobo, Manuel
A1 Bernabe, Reyes
A1 Navarro, Alejandro
A1 Sullivan, Ivana
A1 Trigo, Jose Manuel
A1 Mosquera, Joaquin
A1 Crama, Leonardo
A1 Isla, Dolores
K1 Anti-PD-1/PD-L1 antibodies
K1 Chemotherapy
K1 Immunotherapy
K1 Meta-analysis
K1 Small cell lung carcinoma
AB The addition of immune checkpoint inhibitors (ICIs) to conventional chemotherapy (CT) as first-line treatment improves survival in extensive-stage small-cell lung cancer (ES-SCLC). The aim of this meta-analysis was to determine the relative efficacy of first-line ICIs compared with CT in patients with ES-SCLC. Two independent reviewers extracted relevant data according to PRISMA guidelines and assessed the risk of bias using the Cochrane Collaboration's risk-of-bias tool. Meta-analysis was conducted using random-effects models to calculate an average effect size for overall survival (OS), progression-free survival (PFS), and safety outcomes in the overall populations and clinically relevant subgroups. A literature search of PubMed and Embase was performed. Six randomized controlled clinical trials (IMpower133, CHECKMATE-451, CASPIAN, KEYNOTE-604, and phase II and III ipilimumab plus CT trials) with a total of 3757 patients were included. Compared with CT alone, ICIs plus CT showed a favourable effect on OS (hazard ratio [HR] 0.85; 95% confidence intervals [CI] 0.79-0.96) and PFS (HR 0.78; 95% CI 0.72-0.83) but a non-significant increase in the risk of experiencing any adverse event (relative risk, 1.05; 95% CI 0.99-1.11). The estimated HR for OS favoured ICI combinations in all planned subgroups according to age ( Combining anti-programmed cell death ligand 1 antibodies with platinum/etoposide is a superior therapeutic approach compared to CT alone for the first-line treatment of patients with ES-SCLC.
PB Springer
YR 2022
FD 2022-01-15
LK http://hdl.handle.net/10668/21742
UL http://hdl.handle.net/10668/21742
LA en
NO Arriola E, González-Cao M, Domine M, De Castro J, Cobo M, Bernabé R, et al. Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis. Oncol Ther. 2022 Jun;10(1):167-184
DS RISalud
RD Apr 19, 2025